- Home
- PODD
PODD
Insulet Corporation
as 07-11-2025 3:36pm EST
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | ACTON |
| Market Cap: | 21.5B | IPO Year: | 2007 |
| Target Price: | $320.11 | AVG Volume (30 days): | 767.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 5.55 | EPS Growth: | 67.46 |
| 52 Week Low/High: | $173.00 - $329.33 | Next Earning Date: | 08-07-2025 |
| Revenue: | $2,198,900,000 | Revenue Growth: | 23.48% |
| Revenue Growth (this year): | 24.49% | Revenue Growth (next year): | 17.45% |
Stock Insider Trading Activity of Insulet Corporation (PODD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Manea Dan | PODD | SVP, Chief HR Officer | Jun 13 '25 | Sell | $300.05 | 1,300 | $390,065.00 | 9,090 | |
| BORIO LUCIANA | PODD | Director | Jun 9 '25 | Sell | $305.73 | 481 | $147,056.13 | 3,087 | |
| Kapples John W. | PODD | SVP and General Counsel | May 14 '25 | Sell | $318.47 | 5,278 | $1,680,884.66 | 23,180 | |
| Benjamin Eric | PODD | EVP, CPXO | May 13 '25 | Sell | $320.00 | 3,001 | $960,320.00 | 20,906 | |
| Hopfield Jessica | PODD | Director | May 13 '25 | Sell | $317.54 | 5,235 | $1,662,321.90 | 26,917 |
Latest Insulet Corporation News
PODD Breaking Stock News: Dive into PODD Ticker-Specific Updates for Smart Investing
TipRanks
17 days ago
Diabetes stocks rally after RFK comments on HHS campaign
Argus Research
17 days ago
PODD: Raising target price to $326.00
Barchart
18 days ago
How Is Insulet's Stock Performance Compared to Other Medical Devices Stocks?
Business Wire
23 days ago
Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions
TipRanks
25 days ago
Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls
Investing.com
a month ago
Truist starts on diabetes device makers, sees glucose monitor, insulin pump growth
MT Newswires
a month ago
Truist Initiates Insulet at Buy With $365 Price Target
StockStory
a month ago
1 Cash-Producing Stock with Exciting Potential and 2 to Steer Clear Of
Compare PODD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PODD Insulet Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.